Mesoblast Limited · ASX:MSB
Mesoblast — Investor Day (November 2026)
20 slides from Mesoblast's investor day presentation, Nov 16, 2026
Slide 1: Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases
rsonal use only Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases ASX Investor Day November 2026 ASX: MSB; Nasdaq: MESO
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements rsonal use only This presentation includes forward-looking statements and forecasts that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual res
Slide 3: FY2026: Highlights for the Year and Delivery of Major Milestones
FY2026: Highlights for the Year and Delivery of Major Milestones Successful first year for U.S. commercial launch of RYONCIL • FY2026 net revenue US$115M rsonal use only • Gross profit on total sales, excluding amortization expense, was US$110M Major milestones achieved ✓ Completed 350 patients trea
Slide 4: Our 'MOAT' – Our Market Leadership Position
Our ‘MOAT’ – Our Market Leadership Position ✓ Global IP portfolio >1,100 patents and patent applications provide protection through >2044 ✓ Dominant IP underpins a scalable commercial business model for cell therapy products rsonal use only ✓ First mover advantage – RYONCIL is the first and only MSC
Slide 5: Mesoblast First-In-Class Leader in Allogeneic Cellular Therapies
Mesoblast First-In-Class Leader in Allogeneic Cellular Therapies rsonal use only Ryoncil® Only FDA Approved Rexlemesteocel-L the Engine for Commercial Capability MSC, Successful First US Launch Blockbuster Opportunities Net revenue US$115M in FY2026 – Infrastructure to support product Rexlemestrocel
Slide 6: Mesoblast Worldwide Leader Allogeneic Mesenchymal Stromal Cell Portfolio
Mesoblast Worldwide Leader Allogeneic Mesenchymal Stromal Cell Portfolio Assets Wholly Owned and Unencumbered in U.S. Markets TAM ~US$1B rsonal use only TAM >US$1B TAM >US$1B TAM >US$10B TAM >US$10B This chart is figurative and does not purport to show individual trial progress within a clinical pro
Slide 7: RYONCIL: Steroid-Refractory Acute Graft Versus Host Disease
rsonal use only RYONCIL® Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) 7
Slide 8: Potential Market for RYONCIL Label Extension in Adults
Potential Market for RYONCIL Label Extension as Part of Second-line Regimen Combined with Ruxolitinib in Adults with Grade III/IV aGvHD • >2,000 adults annually in U.S. with SR-aGvHD of which ~50% have Grade III/IV disease rsonal use only • Registration trial: 180 Grade III/IV SR-aGvHD adults random
Slide 9: Rexlemestrocel-L: Chronic Low Back Pain due to Degenerative Disc Disease
rsonal use only Rexlemestrocel-L Chronic Low Back Pain due to Degenerative Disc Disease (CLBP)
Slide 10: Phase 3 Trial to Reduce Inflammation & Pain in Degenerative Disc Disease
Phase 3 trial to Reduce Inflammation & Pain in Degenerative Disc Disease Targeted, minimally invasive delivery of rexlemestrocel-L to the degenerated disc rsonal use only Major Milestones to Commercial Launch 1 P3 trial 350 patients fully enrolled 2 Primary endpoint: 12-month pain reduction Secondar
Slide 11: The Patient Treatment Journey
The Patient Treatment Journey ~7M US patients have moderate / severe DDD within 5 years of diagnosis that is refractory to medical therapies including opioids rsonal use only Rexlemestrocel-L targeting moderate-to-severe CLBP Conservative Opioid Interventional Treatments Surgery Analgesics Therapies
Slide 12: Rexlemestrocel-L: Heart Failure
rsonal use only Rexlemestrocel-L Heart Failure
Slide 13: Cardiopulmonary Indications Leveraging Rexlemestrocel-L Mechanism
Cardiopulmonary Indications Leveraging Rexlemestrocel-L Mechanism LVAD BLA approval for rexlemestrocel-L can open label extension potential in two additional blockbuster indications with same mechanism of action Group 2 Pulmonary rsonal use only End-Stage HFrEF NYHA Class II/III Hypertension with LV
Slide 14: Rexlemestrocel-L Reduces GI Bleeding in End-stage HFrEF Patients with LVADs
Rexlemestrocel-L Reduces GI Bleeding in End-stage HFrEF Patients with LVADs by Reversing Endothelial Dysfunction of GI Blood Vessels Due to Inflammation LVAD II: 6-Month Rate of Major Mucosal Bleeding Events (MMBE) rsonal use only Control Rexlemestrocel-L Subjects from LVAD II Study Nominal (MMBE ra
Slide 15: Group 2 Pulmonary Hypertension (Due to LV Dysfunction)
Group 2 Pulmonary Hypertension (Due to LV Dysfunction) Left-heart disease raises pulmonary pressure and right ventricular load Left-heart disease Pulmonary venous Right ventricular strain rsonal use only hypertension LV or valve disease raises Pressure backs up into Higher pulmonary left atrial pres
Slide 16: Rexlemestrocel-L Improved Survival in HFrEF with Group 2 Pulmonary Hypertension
Rexlemestrocel-L Improved Survival in HFrEF with Group 2 Pulmonary Hypertension in DREAM-HF Trial • In the DREAM-HF population with HFrEF, 219 patients had established Group 2 Pulmonary rsonal use only Hypertension, defined by pulmonary artery systolic pressure (PASP) >35 mmHg, • Across all 219 pati
Slide 17: Group 2 PH: A Large Unmet Need with No Approved Drugs
Group 2 PH: A Large Unmet Need with No Approved Drugs Left heart disease is the most common cause of pulmonary hypertension, creating a substantial addressable population Total Addressable Market for Rexlemestrocel-L rsonal use only 2 GROUP 2 PH - CLINICAL CONTEXT Illustrative patient funnel | Unite
Slide 18: In Summary
rsonal use only In Summary 18
Slide 19: Summary of Major Milestones
Summary of Major Milestones Commercial growth and label expansion for RYONCIL, alongside advancement of rexlemestrocel-L blockbuster programs COMMERCIAL + LABEL BLOCKBUSTER PROGRAM BLOCKBUSTER PROGRAM rsonal use only 1 2 3 EXPANSION RYONCIL® Chronic low back pain Advanced & End-stage heart (remestem
Slide 20: Thank You
rsonal use only Thank You